Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients

doi:10.3748/wjg.v18.i7.698

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 7

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4359)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

368

HTML

3512

Figures (1-4)

263

Tables (1-2)

216

Sum=4359

Feb 21, 2012 (publication date) through Nov 28, 2024

Times Cited of This Article

Times Cited (19)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Feb 21, 2012; 18(7): 698-703
Published online Feb 21, 2012. doi: 10.3748/wjg.v18.i7.698

Full Size Figure Download Figure

Figure 1 Progression-free survival for all patients. Forty-eight patients (92.3%) had disease progression after imatinib 600 mg/d treatment, and the median PFS of all the 52 patients was 17 wk (95% CI: 3.9-30.1). PFS: Progression-free survival; CI: Confidence interval.

Citation: Li J, Gong JF, Li J, Gao J, Sun NP, Shen L. Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients. World J Gastroenterol 2012; 18(7): 698-703
URL: https://www.wjgnet.com/1007-9327/full/v18/i7/698.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i7.698